seen from China
seen from China
seen from United States
seen from Nigeria
seen from United States
seen from China
seen from Czechia
seen from Türkiye
seen from China
seen from Germany
seen from United States
seen from United States
seen from China
seen from Brazil
seen from United States
seen from United States
seen from Australia
seen from United States
seen from United States
seen from China
Olaratumab (Mechanism of Action)
Olaratumab (Mechanism of Action)
In this article, we will discuss Olaratumab (Mechanism of Action). So, let’s get started. Mechanism of ActionOlaratumab is a human IgG1 antibody that binds platelet-derived growth factor receptor alpha (PDGFR-α).PDGFR-α is a receptor tyrosine kinase expressed on cells of mesenchymal origin. Signaling through this receptor plays arole in cell growth, chemotaxis, and mesenchymal stem cell…
View On WordPress
Olaratumab
In this article, we will discuss Olaratumab (Dosage Overview). So, let’s get started. IndicationsOlaratumab is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or…
View On WordPress
Goodbye, Halaven; Hello, Lartruvo
After the complete waste of time that was Halaven, next week I'll be starting on Lartruvo, which was just FDA-approved for soft tissue sarcoma this past October. Because of that, there's not a lot of information about it other than what was released from the clinical trials. But they indicated that it was quite effective. Of course, they said the same thing about Halaven, and a 7-millimeter growth would contradict that.
But onward we go. Naturally, one of the things I've wondered about Lartruvo is how it was named. The generic name is olaratumab, so I'm guessing that the “lar” in “Lartruvo” must have something to do with the “lar” in the generic. Or I could be completely wrong. At this point I don't care what they call any of them -- I'd just like one of them to work.
I'll be getting this drug along with a small amount of Adriamycin, which has been the only drug I've received so far that reduced the nodules (but then I became resistant to it). I'll get the combination for a while and then get the Lartruvo alone, and the clinical trials show that it keeps working even after the Adriamycin is stopped.
We'll find out if it's working some time in mid-May -- just in time for my birthday. Some shrinkage would be a really nice present.
